A5026620381- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Economic and Financial Impacts of Cancer
- Prostate Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- PARP inhibition in cancer therapy
- Health Systems, Economic Evaluations, Quality of Life
- Bone health and treatments
- Lung Cancer Treatments and Mutations
- Esophageal Cancer Research and Treatment
- Cancer, Lipids, and Metabolism
- Cancer Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Hormonal and reproductive studies
- Genital Health and Disease
- Cancer, Hypoxia, and Metabolism
- BRCA gene mutations in cancer
- Inflammatory mediators and NSAID effects
Hospital Universitario Puerta de Hierro Majadahonda
2018-2025
DAK-Gesundheit (Germany)
2019-2025
Hospital Universitario Son Espases
2014-2023
Hospital Universitario Son Dureta
2007-2019
Health Research Institute of the Balearic Islands
2018
Spanish Oncology Genitourinary Group
2013-2016
Corporació Sanitària Parc Taulí
2005
Associazione Italiana Di Oncologia Medica
2001
Germline mutations in DNA damage repair (DDR) genes are identified a significant proportion of patients with metastatic prostate cancer, but the clinical implications these remain unclear. This prospective multicenter cohort study evaluated prevalence and effect germline DDR (gDDR) on castration-resistance cancer (mCRPC) outcomes.Unselected were enrolled at diagnosis mCRPC screened for gDDR 107 genes. The primary aim was to assess impact ATM/BRCA1/BRCA2/ PALB2 cause-specific survival (CSS)...
BackgroundThere is an urgent need to identify biomarkers guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed clinically qualify androgen receptor (AR) gene status measurement plasma DNA using multiplex droplet digital PCR (ddPCR) pre- and post-chemotherapy CRPC.MethodsWe optimized ddPCR assays for AR copy number mutations retrospectively analyzed from patients recruited one of the three biomarker protocols with prospectively collected clinical data. evaluated...
To identify tissue microRNAs predictive of sunitinib activity in patients with metastatic renal-cell-carcinoma (MRCC) and to evaluate vitro their mechanism action resistance.We screened 673 using TaqMan Low-density-Arrays (TLDAs) tumors from MRCC extreme phenotypes marked efficacy resistance sunitinib, selected an identification cohort (n = 41). The most relevant differentially expressed were bioinformatics-based target prediction analysis quantified by qRT-PCR presenting similar independent...
BackgroundPrevious studies suggest that expression of hypoxia markers may be associated with response to antiangiogenic drugs. Thus, we aimed identify predictors sunitinib outcome in clear-cell renal cell carcinoma (ccRCC).Patients and methodsThe eight key proteins related (CAIX, HIF1A, HIF2A, VEGFA, VEGFR1, VEGFR2, VEGFR3 PDGFRB) P-glycoprotein were assessed by immunohistochemistry 67 primary ccRCC samples from prospectively recruited patients treated first-line sunitinib. The expression,...
Mutations in BRCA1 and BRCA2 high penetrance genes account for most hereditary breast ovarian cancer, although other new high-moderate included multigene panels have increased the genetic diagnosis of cancer families by 50%. Multigene provide challenges related to frequency variants uncertain significance, gene-specific risk assessments, clinical recommendations carriers mutations genes. Although criteria testing continue be largely based on personal family history with around a 10%...
Precision medicine in oncology aims to identify the most beneficial interventions based on a patient's individual features and disease. However, disparities exist when providing cancer care patients an individual's sex.To discuss how sex differences impact epidemiology, pathophysiology, clinical manifestations, disease progression, response treatment, with focus data from Spain.Genetic environmental factors (social or economic inequalities, power imbalances, discrimination) that contribute...
The majority of metastatic renal cell carcinoma (RCC) patients are treated with tyrosine kinase inhibitors (TKI) in first-line treatment; however, a fraction refractory to these antiangiogenic drugs. MicroRNAs (miRNAs) regulatory molecules proven be accurate biomarkers cancer. Here, we identified miRNAs predictive progressive disease under TKI treatment through deep sequencing 74 clear RCC cases uniformly Twenty-nine were differentially expressed the tumors who progressed therapy (P values...
The purpose of this study was to describe clinical complications and healthcare resource utilization (HCRU) among patients with sickle cell disease (SCD) recurrent vaso-occlusive crises (VOCs) transfusion-dependent β-thalassemia (TDT) in Germany. Betriebskrankenkasse (BKKs) Database used identify SCD or TDT. To be eligible for inclusion, were required have ≥ 2 VOCs/year any two consecutive years 12 months available data before after the index date (second VOC second year). Patients TDT 8 red...
Abstract Cancer and cancer therapies are a major factor risk for osteoporosis due to bone loss deterioration of microarchitecture. Both factors contribute decrease in strength and, consequently, increased fragility fracture. Cancer-associated is multifactorial process, optimal interdisciplinary management skeletal health, accurate assessment density, early diagnosis essential when making decisions aimed at reducing fracture patients who have received or receiving treatment cancer. In this...
Owing to the limited validity of clinical data on treatment prostate cancer (PCa) and bone metastases, biochemical markers are a promising tool for predicting survival, disease progression skeletal-related events (SREs) in these patients. The aim this study was evaluate predictive capacity turnover mortality risk, SREs patients with PCa metastases undergoing zoledronic acid (ZA). This an observational, prospective multicenter which ninety-eight were included. Patients treated ZA (4 mg every...
Abstract Most muscle-invasive bladder cancer (BC) are urothelial carcinomas (UC) of transitional origin, although histological variants UC have been recognized. Smoking is the most important risk factor in developed countries, and basis for prevention. harbors high number genomic aberrations that make possible targeted therapies. Based on molecular features, a consensus classification identified six different MIBC subtypes. Hematuria irritative symptoms, CT scan, cystoscopy transurethral...
PURPOSE To assess the efficacy and safety of darolutamide maintenance after successful taxane chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS Swiss Group for Clinical Cancer Research (SAKK) 08/16 is a randomized phase II study. Patients mCRPC who received prior androgen-receptor pathway inhibitors (ARPIs) subsequently had nonprogressive disease on were randomly assigned to 600 mg twice day or placebo day. The primary end point was...
In this article, we review de state of the art on management renal cell carcinoma (RCC) and provide recommendations diagnosis treatment. Recent advances in molecular biology have allowed subclassification tumours into different histologic variants may help to identify future prognostic predictive factors. For patients with localized disease, surgery is treatment choice nephron-sparing recommended when feasible. No adjuvant therapy has demonstrated a clear benefit overall survival....